The White House has instructed the National Institutes of Health (NIH) to set up a dedicated women’s health division and has launched a White House taskforce focused on issues affecting female patients. The executive order, signed by President Donald Trump, directs the new unit to be established within 90 days and sets out aims to accelerate scientific discovery, broaden clinical access and modernise care across a woman’s life-course.
A first-lady led policy push
The initiative has been spearheaded by First Lady Melania Trump, who framed the signing as a turning point for women’s health. At the signing ceremony in Washington she described the plan as raising the standard of care and called for faster translation of promising treatments to female patients.
"This is a transformative moment for women in America."
Her office has identified a set of priorities for innovation in the field, described as five pillars. Public details released by the White House highlight two of those aims: directing funding towards targeted research for conditions that disproportionately affect women — with endometriosis given as an example — and shortening the timescale for new therapeutics to reach patients.
Role within NIH and immediate requirements
Officials said the new division will have a broader mandate than research alone and will not supplant the NIH’s existing Office of Research on Women’s Health. The distinction made by the White House suggests the unit is intended to coordinate activity beyond basic research, encompassing clinical access and care modernisation.
The executive order includes a clear deadline: NIH must stand up the division within 90 days. It also establishes a White House-level taskforce to steer the policy direction and priorities associated with the new programme.
What is known so far
- Deadline: new division to be created within 90 days of the order.
- Scope: accelerate scientific discovery, expand clinical access, modernise care throughout women’s lives.
- Relation to existing structures: will not replace the NIH’s Office of Research on Women’s Health but will have a broader remit beyond research.
- Priorities highlighted: funding targeted research (eg, endometriosis) and speeding promising therapeutics to female patients.
The White House also emphasised technological and scientific advances — citing areas such as advanced biotechnology and emerging therapies — as providing a ‘‘unique chance to reinvent women’s healthcare’’. The First Lady said those innovations should allow women not only to prolong life but to live it “to the fullest”.
Context and potential implications
The creation of a dedicated division signals a federal-level attempt to centralise and prioritise women’s health across research, clinical practice and policy. By instructing NIH to act within a 90-day window the administration has prioritised rapid implementation, which could accelerate coordination between research programmes and clinical services.
Key questions remain, and the order as reported does not set out details on funding, staffing, or how the new division will interact operationally with existing NIH institutes and centres. The decision to maintain the Office of Research on Women’s Health indicates an intent for the division to complement rather than replace ongoing research efforts.
Observers will be watching for further announcements from the White House and NIH that clarify the division’s structure, budgetary arrangements and the membership and remit of the White House taskforce. The initiative’s emphasis on targeted research into conditions such as endometriosis and on reducing time-to-patient for new therapies highlights specific areas where advocates and clinicians have long sought greater attention.
| Item | Details reported |
|---|---|
| Establishment deadline | 90 days |
| Relationship to existing NIH office | Will not replace the Office of Research on Women’s Health |
| Highlighted priorities | Targeted research (eg, endometriosis); faster access to therapeutics |
As the NIH prepares to implement the order, stakeholders from patient groups to researchers will be assessing whether the new division brings tangible changes in research investment, clinical pathways and the speed at which scientific advances reach women in the clinic.
